Industry News
Patients With Serious Blood Clot Risk Detected By New Risk Score
Aug 18, 2011
A study published on bmj.com yesterday revealed a new risk prediction tool that can identify patients at high risk of serious blood clots (known as venous thromboembolism) who might require preventative treatment... Read More
Man's Best Friend Able To Sniff Out Lung Cancer Before Doctors Detect
Aug 18, 2011
Man's best friend, the dog, may also be a lifesaver. New research finds that super trained pups are able to sniff out lung cancer in a human's breath, making detection easier and earlier for doctors. This will allow them to treat the ailment earlier and save more lives. Nice... Read More
Risk Of Bladder Cancer Due To Smoking Higher Than We Thought
Aug 18, 2011
According to a study in the August 17 issue of JAMA, an analysis of data from almost 500,000 individuals indicates, that the risk of bladder cancer among smokers is higher than reported from previous population data, and that the risk for female smokers is comparable with that of men... Read More
Sex After Prostate Surgery And New Techniques To Improve It
Aug 18, 2011
Dr. David Samadi, Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center knows the wide range of emotions and fears that men with prostate cancer face. As a robotic prostatectomy and prostate cancer treatment expert, Dr. Samadi cares for the total patient, helping them deal with all aspects of treatment, recovery and cure... Read More
FDA Approves Zelboraf And Companion Diagnostic Test For Late-Stage Skin Cancer
Aug 18, 2011
The U.S. Food and Drug Administration approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer. Zelboraf is specifically indicated for the treatment of patients with melanoma whose tumors express a gene mutation called BRAF V600E... Read More
Roche's FDA Approved Zelboraf Fights War Against Melanoma Gene Variant
Aug 18, 2011
Melanoma has been considered one of the toughest cancers to treat, with few drug options...until now. The FDA has approved Roche's unique acting drug for melanoma, the deadliest form of skin cancer. Zelboraf (vemurafenib) works by targeting a mutant gene that's found in about half of melanoma patients. This makes two drugs approved that direct confront the deadly disease, a form of skin cancer... Read More
FDA Approval Of Zelboraf™ (vemurafenib) Establishes Oncology Foothold In US For Daiichi Sankyo
Aug 18, 2011
With the US Food and Drug Administration (FDA) approval of Zelboraf™ (vemurafenib), a first-in-class personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test, Daiichi Sankyo prepares to enter the US cancer market with its first oral, targeted anti-cancer therapy... Read More
Blocking Cancer Cell's Energy 'Generator' Could Lead To New Targeted Treatments
Aug 18, 2011
CANCER RESEARCH UK scientists have found that blocking the pathway used by some kidney cancer cells to generate energy can kill the cancer cells, sparing the healthy ones. The research is published in Nature today (Wednesday). Cells need energy to grow and divide... Read More
Blood Vessels Participate In The Eradication Of Tumors
Aug 18, 2011
Breast cancer: for the first time, very specific blood vessels have been discovered in tumors. These vessels facilitate the access of certain white blood cells, known as "killer lymphocytes", into tumor tissues and thus lead to the efficient destruction of tumors... Read More
Flexible-fiber CO2 Laser Proves Safe In Endoscopic Endonasal Transsphenoidal Surgery
Aug 18, 2011
A new study has shown the Flexible-Fiber CO2 laser to safely cut and coagulate during endoscopic assisted transsphenoidal craniotomies (TSC) without the line of sight problems encountered with conventional CO2 lasers. The findings, reported by researchers from Boston Medical Center (BMC) and Boston University School of Medicine (BUSM), appear in the July/August issue of World Neurosurgery... Read More
Previous Page Next Page